Healthcare Industry News: NPWT
News Release - October 14, 2011
NovaBay Pharmaceuticals Spotlights NeutroPhase(R) at the Symposium on Advanced Wound Care (SAWC)NeutroPhase is a FDA 510(k) cleared advanced wound care product addressing the un-met medical needs of the six-million-patient USA chronic wound care market
EMERYVILLE, Calif., Oct. 14, 2011 -- (Healthcare Sales & Marketing Network) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage biotechnology company developing non-antibiotic anti-infective agents for topical non-systemic applications, today announced the first introduction of NeutroPhase at the Symposium on Advanced Wound Care (SAWC) from October 13-15 at the Rio Hotel & Casino in Las Vegas, Nevada at booth #525.
NeutroPhase is the only pure, isotonic stable hypochlorous acid solution that is packaged in a convenient glass container which will insure its long-term shelf stability. Hypochlorous acid is an anti-biofilm, broad-spectrum, antimicrobial agent while being safe and well-tolerated in human tissues.
NovaBay's CEO Ron Najafi, PhD said: "Our main objective is to introduce NeutroPhase to wound care specialists who treat patients with chronic non-healing wounds. Chronic non-healing wounds are a serious unmet clinical need, and we strongly believe NeutroPhase offers a new and better standard of care. We anticipate a market launch in 2012."
Dr. Najafi will present NeutroPhase at a breakfast symposium on Saturday morning, October 15 to highlight the value of NeutroPhase for Wound Care in accelerating the healing of chronic non-healing wounds. Professor Robert S. Kirsner, MD, PhD, vice chairman and Stiefel Laboratories, Chair of the Department of Dermatology & Cutaneous Surgery and Chief of Dermatology at the University of Miami School of Medicine will be presenting on management of bacterial biofilm in wound care and will be moderating the session. Additionally, John Crew, M.D. vascular surgeon at the San Francisco Wound Care Center - Seton Medical Center will present selected examples of the more than 30 clinical cases studied using NeutroPhase with and without negative pressure wound therapy (NPWT) to accelerate the healing of chronic non-healing wounds. Factors contributing to the impairment of healing such as the presence of bacterial infection, drug resistant bacteria, biofilm, tissue maceration, ischemia, venous stasis, and foreign bodies will be discussed. The audience is expected to consist of approximately 125 vascular surgeons, dermatologists and wound care nursing specialists.
NovaBay is targeting the six-million-patient market of chronic non-healing wounds, such as pressure, venous stasis and diabetic ulcers with its proprietary solution, NeutroPhase, which has received two 510(k) clearances from the Food and Drug Administration as a wound cleanser. NeutroPhase consists of pure and stable hypochlorous acid in saline packaged in a glass container. Hypochlorous acid is the same agent produced by white blood cells which defend against bacteria. The solution has been shown not to harm living cells and is rapidly effective against common wound pathogens. The characteristics and mechanisms of action of NeutroPhase make it highly unlikely that resistant strains of bacteria could develop over time.
About NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals is a clinical-stage biotechnology company focused on developing its proprietary and patented Aganocide compounds. These are novel, synthetic anti-infectives with activity against bacteria, fungi and viruses, and are being developed to treat and prevent a wide range of local, non-systemic infections with a low likelihood of developing bacterial resistance.
NovaBay is focusing its technology on four distinct therapeutic areas: dermatology, ophthalmology, urology and hospital infections. In dermatology, the focus is on developing an NVC-422 gel formulation for the highly contagious skin infection of impetigo. NovaBay has the advantage of being partnered with Galderma, the leading dermatology company in the world. In ophthalmology, the goal is to develop an eye drop for viral conjunctivitis. In urology, NovaBay aims to reduce the incidence of urinary catheter blockage and encrustation (UCBE) and the potential for urinary tract infections with an irrigation solution containing NVC-422. In hospital infection, NovaBay is targeting the six-million-patient market of chronic non-healing wounds, such as pressure, venous stasis and diabetic ulcers with its proprietary anti-infective solution, NeutroPhase, which has received two 510(k) clearances from the Food and Drug Administration. For additional information, visit www.novabaypharma.com.
Cautionary Information Regarding Forward-Looking Statements
This release contains forward-looking statements, which are based upon management's current expectations, assumptions, estimates, projections and beliefs. The statements in this press release including, but not limited to, statements regarding NovaBay's expectations on the value of NeutroPhase for Wound Care in accelerating the healing of chronic non-healing wounds; the anticipated market launch of NeutroPhase in 2012 as well as other statements that relate to future events or results are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward- looking statements reflect the views of the management of NovaBay as of the date of this press release and are based on assumptions and subject to significant risks and uncertainties (many of which are outside of NovaBay's control), including: the risk that NovaBay's Aganocide compounds and NeutroPhase may not prove to be effective in treating wounds; the risk that NovaBay may experience unexpected results in further studies which may limit, delay or prevent NovaBay from manufacturing NeutroPhase; unexpected adverse side effects or inadequate therapeutic efficacy of NeutroPhase may inhibit it from becoming a treatment for chronic wound and the risk of unexpected delays in the regulatory process which may delay the manufacturing and potential marketing of NeutroPhase, as well as other risks relating to NovaBay and its Aganocide compounds detailed in NovaBay's Quarterly Report on Form 10-Q, under the caption "Risk Factors" in Item 1A of Part II of that report, which was filed with the Securities and Exchange Commission on August 10, 2011. The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
Source: NovaBay Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.